Change in NAV (30/06/2025)
Since previous NAV (N/A)
Recommended Holding Period
Risk and Reward Profile
The Fund’s investment strategy is designed to maximize value creation towards its Investors, by leveraging on its Management Team’s expertise across a broad range of sectors and its substantial experience in the field of innovations in biotech and longevity. To achieve its strategic goals, the fund intends to have stake in the future high-growth longevity businesses by supporting them early.
Inception Date (Fund):
01/03/2021
Legal form:
RAIF
Benchmark:
N/A
Currency (Fund):
EUR
Distribution Policy:
Distributable net proceeds from liquidation of any Portfolio Investments shall be apportioned among both Investors and the External Manager (and/or Expert Advisors) in proportion to their Sharing Percentages.
Valuation frequency:
Quarterly
Minimum initial investment:
EUR 500,000
ISIN Code:
CYF000001877
AuM (Fund):
EUR 19.96M
Regulatory authority:
CySEC
Management company:
7Q Asset Management Ltd
Delegated Management Company:
N/A
Incorporation:
Cyprus
Management fee:
2.50% annually, capped at 15%
Subscription conditions:
Quarterly (last business day of each quarter)
Redemption conditions:
Is the Exit period which takes place after the maturity of the Fund and where the term of the scheme ends
Lock Up Period:
6+1 Years
Subscription fee:
N/A
Performance fee:
N/A